UNSPSC 51381516: Tolmetin sodium dihydrate

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C15H14NO3.Na.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 02N1TZF99F, chemically known as 1h-pyrrole-2-acetic acid, 1-methyl-5-(4-methylbenzoyl)-, sodium salt, dihydrate, but more generally known as tolmetin sodium dihydrate, which bears US NIH Compound Identifier 47400. European Medicines Agency schedules tolmetin sodium dihydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11162MIG.

Most nations, for tariff purposes, schedule tolmetin sodium dihydrate under HS 29339990. SMILES: CC1CCC(CC1)C(=O)C2CCC(N2C)CC(=O)[O-].O.O.[NA+].

UNSPSC 51381516 Tolmetin sodium dihydrate is a Commodity code that does not align with the state and local procurement activity currently tagged to it. The recent opportunities solicited under this code involve naloxone, safe drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products — none of which are tolmetin sodium dihydrate, a nonsteroidal anti-inflammatory drug. The mismatch suggests either a data-classification error in the source material or inconsistent tagging by the issuing jurisdictions. State and local governments do procure pharmaceuticals through competitive bidding and cooperative purchasing arrangements, but the specific pharmaceutical in this code's nominal scope does not appear in recent solicitation activity.

The three recent opportunities represent distinct procurement approaches across different issuing bodies: Seminole County, Florida issued an IFB for naloxone and drug deactivation systems with a July 26, 2023 response date; the Texas Health and Human Services Commission issued an RFI on April 3, 2026 exploring direct-to-manufacturer prescription capabilities; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP due March 26, 2026 for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers to state and local facilities across participating jurisdictions including Oregon. Given the code's disconnect from the actual work being solicited, this code shows little decision-relevant recent activity for business development purposes focused on tolmetin sodium dihydrate or its close pharmaceutical equivalents.